期刊簡介 | |||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名稱 | Clinical Proteomics LetPub Score 6.0
50 ratings
Rate
Reputation 7.1 Influence 4.8 Speed 7.0 | ||||||||||||||||||||||||
期刊簡稱 | CLIN PROTEOM | ||||||||||||||||||||||||
ISSN | 1542-6416 | ||||||||||||||||||||||||
E-ISSN | 1559-0275 | ||||||||||||||||||||||||
h-index | 25 | ||||||||||||||||||||||||
CiteScore |
| ||||||||||||||||||||||||
自引率 (2023-2024) | 3.60%自引率趨勢 | ||||||||||||||||||||||||
掲載範囲 |
| ||||||||||||||||||||||||
官方網站 | https://www.springer.com/journal/12014 | ||||||||||||||||||||||||
在線稿件提交 | https://www.editorialmanager.com/CLIP | ||||||||||||||||||||||||
開放訪問 | Yes | ||||||||||||||||||||||||
出版商 | BioMed Central | ||||||||||||||||||||||||
主題領域 | BIOCHEMICAL RESEARCH METHODS | ||||||||||||||||||||||||
出版國/地區 | ENGLAND | ||||||||||||||||||||||||
發行頻率 | |||||||||||||||||||||||||
創刊年 | 2004 | ||||||||||||||||||||||||
每年文章數 | 52每年文章數趨勢 | ||||||||||||||||||||||||
黃金OA百分比 | 99.24% | ||||||||||||||||||||||||
OA Related Info | APC: Yes( EUR2090; USD2490; GBP1790; ) APC waiver:Check Notes Other charges: No Keywords: translational proteomics、molecular medicine Useful LinksAims & ScopeAuthor InstructionsEditorial BoardAnonymous peer review | ||||||||||||||||||||||||
Web of Science 四分位 ( 2023-2024) | WOS Quartile: Q2
| ||||||||||||||||||||||||
索引 (SCI or SCIE) | Science Citation Index Expanded | ||||||||||||||||||||||||
鏈接到PubMed Central (PMC) | https://www.ncbi.nlm.nih.gov/nlmcatalog?term=1542-6416%5BISSN%5D | ||||||||||||||||||||||||
平均審稿時間 * | 來自出版商的數據: 來自作者的數據: 17 Weeks | ||||||||||||||||||||||||
競爭力 * | 來自作者的數據: | ||||||||||||||||||||||||
參考鏈接 |
| ||||||||||||||||||||||||
*所有的審稿過程指標,如接受率和審稿速度,僅限於用戶提交的稿件。因此,這些指標可能無法準確反映期刊的競爭力或速度。 |
|
|
首頁 上一頁 1 下一頁 末頁 (頁 | |
[Clinical Proteomics] 的評論 | 撰寫評論 |
作者: 小野寺心宜 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-04-18 10:53:38 評論於 Review speed: 1.0 | Submission acceptance rate: 50.0 Emphasis on research directions: Proteomics and metabolomics Experience sharing: Slow(0) 讚! | 小野寺心宜 |
作者: 一条小如之 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-03-03 21:58:24 評論於 If you don't want to end up unhappy, trust me, don't invest(0) 讚! | 一条小如之 |
作者: 一条小如之 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-01-21 15:24:44 評論於 It took three months for the first reviewer to agree to review(0) 讚! | 一条小如之 |
作者: 一条小如之 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2022-11-02 17:36:41 評論於 Review Speed: 6.0 Experience Sharing: Really slow, it took the editor a month to decide to submit for review, I guess the editor is not working(0) 讚! | 一条小如之 |
作者: MACAUHK 領域: 生物学 審稿時間: 5.0 month(s) 結果: 修改後接受 撰寫評論 |
2022-04-27 14:57:26 評論於 It's okay, the clinical data review is strict, and all the reviewers are clinical experts.(0) 讚! | MACAUHK |
作者: 维尔娜菲茨杰拉德 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-12-30 23:09:25 評論於 Condense around their own hypothesis or innovative points. The standard for the best title is to accurately describe the content of the paper using the fewest necessary terms. Writing requirements are accuracy, brevity, clarity, and attractiveness(0) 讚! | 维尔娜菲茨杰拉德 |
作者: 维尔娜菲茨杰拉德 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-12-30 13:08:56 評論於 Most journals have specific requirements for articles, as well as a checklist that can be used as a reference. You can also refer to articles already published in the target journal when writing(0) 讚! | 维尔娜菲茨杰拉德 |
作者: Darlene Pepys 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-12-27 09:12:13 評論於 Is there a writing template for SCI articles?(0) 讚! | Darlene Pepys |
作者: 深渊兴业 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-12-26 11:52:11 評論於 How to refine/write article titles?(0) 讚! | 深渊兴业 |
作者: 拈花振杰 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2019-09-29 15:57:36 評論於 How much is the fee for this?(0) 讚! | 拈花振杰 |
作者: 一只昊昊呀 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2018-09-04 12:50:11 評論於 Review speed: 3.0 | Submission acceptance rate: 50.0 Experience sharing: A very slow paying journal!(0) 讚! | 一只昊昊呀 |
首頁 上一頁 1 下一頁 末頁 (頁 |
Contact us